Homology Medicines, Inc. (FIXX) financial statements (2020 and earlier)

Company profile

Business Address ONE PATRIOTS PARK
BEDFORD, MA 01730
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments262270296188215238256
Cash and cash equivalents547811641383695
Short-term investments209192180147177202161
Deferred costs   0   
Other undisclosed current assets4432786
Total current assets:267274299191222246262
Noncurrent Assets
Property, plant and equipment4341414136217
Other undisclosed noncurrent assets1112222
Total noncurrent assets:4443424337239
TOTAL ASSETS:311317341233259268270
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities814121420147
Accounts payable3981216115
Accrued liabilities1111000
Employee-related liabilities5432322
Deferred revenue11  
Deferred rent credit11111  
Contract with customer, liability11   
Other undisclosed current liabilities2321554
Total current liabilities:12191518251911
Noncurrent Liabilities
Liabilities, other than long-term debt40404141973
Deferred revenue3030  
Contract with customer, liability3131   
Deferred rent credit10101011973
Other undisclosed noncurrent liabilities    293030
Total noncurrent liabilities:40404141393733
Total liabilities:52595659645644
Stockholders' equity
Stockholders' equity attributable to parent259258285174195213227
Common stock0000000
Additional paid in capital458433430294292291290
Accumulated other comprehensive income (loss)0000(0)(0)(0)
Accumulated deficit(200)(176)(146)(120)(97)(78)(64)
Total stockholders' equity:259258285174195213227
TOTAL LIABILITIES AND EQUITY:311317341233259268270

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:1000111
Operating expenses(26)(32)(28)(25)(21)(17)(15)
Operating loss:(26)(31)(28)(25)(20)(16)(14)
Nonoperating income
(Other Nonoperating income)
1221111
Net loss available to common stockholders, diluted:(24)(30)(26)(24)(19)(15)(13)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(24)(30)(26)(24)(19)(15)(13)
Comprehensive loss:(24)(30)(26)(24)(19)(15)(13)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)000(0)00
Comprehensive loss, net of tax, attributable to parent:(24)(30)(26)(24)(19)(15)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: